Skip to main content
. 2011 Mar 1;10(2):87–97. doi: 10.1007/s11901-011-0096-0

Table 2.

Sensitivity analyses of FibroTest diagnostic values according to patient characteristics

Advanced fibrosis Pairwise comparisons between all stages, Obuchowski measure
Characteristic (no. of patients) Not standardized AUROC Significance (P) AUROC (95% CI)
All (1303) 0.76 (0.73–0.79) 0.844 (0.832–0.856)
Gender >0.10
Male (941) 0.75 (0.72–0.78)
Female (362) 0.76 (0.70–0.81)
Length of biopsy >0.10
<25 mm (942) 0.76 (0.71–0.85)
≥25 mm (148) 0.79 (0.71–0.85)
Not available (213) 0.76 (0.69–0.82)
Ethnicitya 0.06 P > 0.10
Asian (546) 0.72 (0.67–0.76) 0.836 (0.814–0.848)
Caucasian (601) 0.78 (0.74–0.82) 0.853 (0.839–0.867)
Sub-Saharan (156)b 0.80 (0.72–0.86)
HBeAgc,d 0.046 P > 0.10
Absent (548) 0.73 (0.68–0.77)e 0.854 (0.838–0.870)
Present (753) 0.78 (0.75–0.82) 0.831 (0.814–0.848)
After treatment >0.10
No (723) 0.75 (0.71–0.78)
Yes (392) 0.78 (0.72–0.82)
Not available (188) 0.78 (0.70–0.85)
HBV genotype >0.10
Genotype A (61) 0.77 (0.57–0.88)
Genotype non-A (137) 0.77 (0.73–0.79)
Not available (1105) 0.76 (0.73–0.79)
Viral load (IU/mL) >0.10
<3 Log (276) 0.79 (0.73–0.84)
3–5 Log (115) 0.82 (0.72–0.88)
5–7 Log (330) 0.72 (0.66–0.77)
>7 Log (464) 0.77 (0.72–0.81)
Not available (118) 0.76 (0.65–0.83)
ALT <50 IU/L >0.10
No (825) 0.75 (0.72–0.79)
Yes (478) 0.76 (0.70–0.80)
ALT <25 IU/L >0.10
No (1151) 0.76 (0.73–0.79)
Yes (152) 0.72 (0.57–0.82)

aIn Asian patients (n = 546) the overall mean (95% CI) accuracy of FibroTest (standardized using Obuchowski measure) was 0.827 (0.807–0.846), no different than that of non-Asian (n = 757), 0.853 (0.839–0.867), (NS)

bAfrican American also included

cIn 2 patients, status was unknown

dIn patients with presence of HBeAg (n = 753) the overall mean (95% CI) accuracy of FibroTest (standardized using Obuchowski measure) was 0.831 (0.814–0.848), no different than that of patients without HBeAg (n = 548), 0.854 (0.838–0.870), (NS)

e P = 0.046 vs “present”

ALT alanine aminotransferase, AUROC area under the receiver operating curve, HBeAg hepatitis B early antigen, HBV hepatitis B virus